KaloBios shares tank on failed asthma drug trial – San Francisco Business Times (blog)

KaloBios shares tank on failed asthma drug trial
San Francisco Business Times (blog)
KaloBios (NASDAQ: KBIO), which has seen its stock price tumble since it raised $70 million in an initial public offering a year ago, will discontinue clinical development of the drug, called KB-003, in severe asthma. The monoclonal antibody was safe
KaloBios to Stop KB003 Development for AsthmaZacks.com
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
Wall Street Journal
all 31 news articles »

View full post on asthma – Google News